Literature DB >> 8556449

[Effects of substituted dextran on reinnervation of a skeletal muscle in adult rats during regeneration].

A Aamiri1, A Mobarek, G Carpentier, D Barritault, J Gautron.   

Abstract

RGTA11 is a chemically substituted dextran that mimics some of the properties of heparin or heparan sulphates towards heparin binding growth factors as well as inhibits some heparin binding proteases. In vivo RGTA11 has been shown to enhance muscle regeneration after crush. We now present evidence that RGTA11 can alos favour reinnervation of fast (EDL) as well as slow (soleus) crushed muscles. Both types of muscles were injected with RGTA11 after crushing and nerve cutting. In EDL muscles, after 16 days, motor end plates were more rapidly reformed and choline acetyl-transferase activity was 2 fold higher than in controls. In soleus muscles, after 16 days, motor end plates were reformed at normal size while controls were on average 30% smaller, the 16S form of acetyl-cholinesterase and choline acetyl-transferase activity were twice those of non injected regenerating controls. In conclusion, RGTA11 favours axonal growth and synaptic differentiation, allowing a more rapid reinnervation and maturation of the regenerated fibers. RGTA may present a new family of drugs against neuromuscular degenerescence.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8556449

Source DB:  PubMed          Journal:  C R Acad Sci III        ISSN: 0764-4469


  4 in total

Review 1.  Stewart-Bluefarb syndrome: review of the literature and case report of chronic ulcer treatment with heparan sulphate (Cacipliq20®).

Authors:  Shady Hayek; Bishara Atiyeh; Elias Zgheib
Journal:  Int Wound J       Date:  2013-04-05       Impact factor: 3.315

2.  Refractory sickle cell leg ulcer: is heparan sulphate a new hope?

Authors:  Shady Hayek; Saad Dibo; Joe Baroud; Amir Ibrahim; Denis Barritault
Journal:  Int Wound J       Date:  2014-02-21       Impact factor: 3.315

3.  Reversal of abnormal collagen production in Crohn's disease intestinal biopsies treated with regenerating agents.

Authors:  C Alexakis; J P Caruelle; A Sezeur; J Cosnes; J P Gendre; H Mosnier; L Beaugerie; D Gallot; M Malafosse; D Barritault; P Kern
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

Review 4.  RGTA® or ReGeneraTing Agents mimic heparan sulfate in regenerative medicine: from concept to curing patients.

Authors:  Denis Barritault; Marie Gilbert-Sirieix; Kim Lee Rice; Fernando Siñeriz; Dulce Papy-Garcia; Christophe Baudouin; Pascal Desgranges; Gilbert Zakine; Jean-Louis Saffar; Johan van Neck
Journal:  Glycoconj J       Date:  2016-12-07       Impact factor: 2.916

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.